TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05830448

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: The trial was planned to have a three-month announcement and an eight-week intervention period. Personal information form, Perceived Stress Scale, Coping with Stress Scale, Connor-Davidson Resilience Scale, Quality of Life Scale for Employees will be used in the pre-test phase of data collection. Participants meeting the inclusion criteria will be randomly assigned to the intervention and control groups. In order to support nurses in the intervention group to gain awareness of stress and anxiety and develop positive coping skills, 8 sessions of 40 minutes were planned, including interaction steps based on education and cognitive approach. As of the second week, homework will be given to individuals and they will be asked to submit these assignments to the researcher 2 days before the next interview. Participants who do not submit the assignments given in this study to the researcher on time will be excluded from the study even if they have completed the training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: T.R. Mobile Mental Health Support System produced by the Ministry of Health
Description: No intervention will be applied to the individuals assigned to the control group by the researcher. Participants will be informed about the Mobile Mental Health Support System created by the Turkish Ministry of Health and will be directed to this application.
Study: NCT06379074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improving sleep health and resilience during pregnancy
Description: Weekly sessions include: a video clip (ca. 20 min) and a pdf; short questions on participants' experience related to the session's content; brief feedback questions on session's contents. Participants will have weekly opportunity for private online chats with a clinician.~Sessions' contents:~1. Aims of the intervention; introducing the physiological regulation of sleep, sleep health and how sleep changes during pregnancy;~2. Psychological regulation of sleep and the impact of behaviors on sleep regulation; introducing the basics of CBT-I behavioral techniques;~3. Cognitive factors maintaining sleep difficulties; introducing cognitive techniques;~4. Emotional factors maintaining sleep difficulties and on the bidirectional association between sleep and emotions; introducing emotion regulation techniques;~5. Sleep in the postpartum and the development of sleep regulation in children;~6. Relapse prevention and focus on acquired skills and how to prioritize sleep.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information on pregnancy-related issues
Description: Each session will include: video clip (ca. 20 minutes) on aspects related to pregnancy and sleep; brief feedback questions. Participants in the placebo intervention will not be given specific indications on skills or techniques for sleep difficulties and will not have access to the weekly chat with the clinician.~Sessions will cover the following contents:~Session 1: phases of pregnancy; Session 2: sleep disorders; Session 3: nutrition and physical activity during pregnancy; Session 4: childbirth; Session 5: psychophysical development of the child in the first three years of life; Session 6: synthesis of previous sessions.
Study: NCT06373432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingerstick
Description: Fingerstick to check glucose value during labor.
Study: NCT05756855

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted behavioral intervention
Description: cognitive behavioral therapy based intervention that focuses on anger, violence, and psychosis
Study: NCT05229068

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV MAT
Description: Single 120 µg dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
Study: NCT06299761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-825
Description: Oral RNR inhibitor
Study: NCT04999163

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortix System
Description: Aortix is indicated as a partial circulatory support device to increase renal perfusion and reduce the incidence of acute kidney injury (AKI) in patients undergoing cardiac surgery who are at heightened risk of developing AKI.
Study: NCT04715074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interviews
Description: We will understand the impact psychosocial, lifestyle, and familial aspects play on an EOCRC diagnosis through 20 one-hour interviews with EOCRC patients and survivors.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pilot
Description: Utilizing the Behaviour Change Wheel in conjunction with results gathered from Aims 1 and 2 we will develop a theory-driven, multi-media campaign intervention to increase awareness of EOCRC, risk factors, and early detection benefit.
Study: NCT05105594

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey application
Description: Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: survey application
Description: Fear of movement will be evaluated with the Kinesiophopia Causes Scale. It is a 20-question survey in which the causes of fear of movement are investigated. Functional Evaluation of Treatment of Fatigue Chronic Disease will be assessed by the Fatigue Questionnaire. It consists of 13 questions assessing the level of fatigue during daily activities in the last 7 days. Quality of Life will be assessed by the Lymphedema Quality of Life Questionnaire.
Study: NCT06111859

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound based Elastography and fat quantification
Description: Correlation of ultrasound-based elastography and fat quantification on liver biopsy
Study: NCT06241170

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mesentery-guided resection margin
Description: The research team positions the proximal margin of the anastomosis in a way that the mesentery reaches the point of being palpable and where the fat appears entirely normal under direct visual observation, in contrast to the mesentery near the proximal and distal ends of the anastomosis.
Study: NCT05159375

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Elio
Description: Elio™ supplementation, a protein hydrolysate derived from fava bean protein extract

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: SMCC
Description: Placebo comparator
Study: NCT06429787

Intervention type: DRUG
Intervention: Balfaxar
Description: BALFAXAR (prothrombin complex concentrate, human-lans) is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for an urgent surgery/invasive procedure

Intervention type: DRUG
Intervention: Kcentra
Description: KCENTRA, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with:~* acute major bleeding or~* need for an urgent surgery/invasive procedure
Study: NCT05657561

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Mobilization training was given to the intervention group.
Study: NCT05875896

Intervention type: PROCEDURE
Intervention: Total wrist fusion
Description: Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate

Intervention type: PROCEDURE
Intervention: Total wrist fusion
Description: Observation after implantation of Medartis Aptus Wrist Arthrodesis Plate
Study: NCT05263089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PALFIQUE® Universal Flow; Tokuyama, Tokyo, Japan (super low flowability)
Description: Supplied in L-syringe with nozzle and dispensing Tips. Super Low has low flowability, non-slumping, non-running, and precision stacking properties. The layer dispensed will be 2 mm. in thickness and cured for 40 s.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ESTELITE® Alpha; Tokuyama, Tokyo, Japan
Description: The composite was inserted using the incremental technique. Each increment of 2 mm was cured for 40 s.
Study: NCT06067555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections
Study: NCT05904665

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ctDNA methylation dynamic monitoring
Description: ctDNA methylation detection is performed within one month before surgery, within one month after surgery, and every three months after surgery, for a period of 2 years.
Study: NCT05125770

Intervention type: BIOLOGICAL
Intervention: New crown vaccine
Description: New Coronavirus vaccine
Study: NCT06067555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MicronJet
Description: MicronJet 600 syringe will be used to administer intradermal flu vaccine injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® Quadrivalent
Description: Intradermal injections of 0.3mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® Quadrivalent
Description: Intramuscular injection of 0.3mL

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic Saline
Description: Intradermal injection of 0.3mL (control)
Study: NCT06052696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gardasil 9 Suspension for Injection
Description: After randomisation in the Gardasil arm, women will receive 3 Gardasil vaccinations~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: After randomisation in the PLacebo arm, women will receive 3 Placebo vaccination with NaCl 0.9%~1. First injection: preferable at time of start treatment (imiquimod, lase or surgery). Window 4 weeks prior to treatment start (because surgical treatment can be postponed for logistical reasons) and 4 weeks after start treatment.~2. Second injection: should be administered at least 1 month after the first injection and 3 months before the third injection.~3. Third injection should be administered at 3 months after second injection. All injections should be administered within 1 year.
Study: NCT06067555

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Bacteriostatic Saline
Description: Intradermal injection of 0.3mL (control)
Study: NCT03037814

Intervention type: DEVICE
Group type: OTHER
Intervention: Amalgam
Description: Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.

Intervention type: DEVICE
Group type: OTHER
Intervention: Amalgam
Description: Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
Study: NCT03037814

Intervention type: DEVICE
Group type: OTHER
Intervention: Amalgam
Description: Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
Study: NCT06475755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunochemotherapy combined with antiangiogenic
Description: neoadjuvant： Tislelizumab 200mg iv，d1，q3w， Anlotinib 10mg，po，qd1-14，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].

Intervention type: DRUG
Group type: OTHER
Intervention: Immunochemotherapy
Description: neoadjuvant：Tislelizumab 200mg iv，d1，q3w， Cisplatin 75 mg/m\^2 by IV infusion Q3W, given on cycle day 1 Carboplatin AUC of 5 on Day 1 of each 3-week cycle Paclitaxel 175mg/m2 on Day 1 of each 3-week cycle(SQ only) Albumin-bound paclitaxel 260mg/m2，on D1 IV infusion Q3W or 130mg/m2 on D1D8 IV infusion Q3W for each cycle(SQ only) Pemetrexed 500 mg/m2 on Day 1 of each 3-week cycle(NSQ only) Adjuvant: 4 weeks(±7 Days) following surgery, participants receive no more than 16 cycles (cycle length: 3 weeks) of Tislelizumab \[200 mg, IV; given on cycle day 1\].
Study: NCT05225623

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BWLT
Description: This group will attend 16 2-hour group-based weekly sessions in Small Changes BWLT in addition to their treatment at the Balfour Medical Clinic

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control for BWLT
Description: This group will receive treatment as usual at the Balfour Medical Clinic and put on a waitlist for the Small Changes BWLT program
Study: NCT04914793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Antimicrobial prescribing guideline mobile phone application (MicroGuide)
Description: This session is given to all hospital doctors in all study hospitals at the start of the intervention period of each paired hospital. All participating hospitals will join AMS knowledge survey three times during the study period (1st time= at the start of the project, 2nd time= before entering to the intervention period and 3rd time= at the end of the project).
Study: NCT05025332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2591
Description: NNZ-2591 oral solution (50mg/mL) to be administered twice daily dose for 13 weeks.
Study: NCT06114056

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JWK007 Single intravenous infusion administration
Description: Six male children aged 5-10 years were enrolled in the study. The patients were divided into two different dose groups, and a 3+3 dose escalation design was used, the low dose was 1.0×1014vg/kg, and the high dose was 2.0×1014vg/kg. Only one intravenous infusion of JWK007 was administered to each patient.
Study: NCT05125848

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: The CM-1500 is a U.S. FDA cleared non-invasive monitoring device that simultaneously monitors five (5) parameters of a patient's body. A combination of these parameters is represented by a single number known as the Relative Index value. This value is indicative of relative changes in fluid volume.
Study: NCT06248372

Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
Study: NCT04888390

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muti-model exercise intervention
Description: The Muti-model exercise intervention include aerobic exercise training by ergometer or treadmill, resistance exercise by using elastic band and flexibility exercise by active stretch. The total training program takes for 60 minutes, 2-3 times per week for 3 months.
Study: NCT05621538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Realtime fMRI Neurofeedback - Active
Description: fMRI aided reinforcement of craving regulation
Study: NCT06248372

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Both groups will receive the same exercise program that includes strengthening and stretching exercises except for the verbal instructions which shift attention to the internal or external environment or no attentional instructions for the control group.
Study: NCT06383897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10398
Description: SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10398
Description: SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10398
Description: SAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14 IRF：HS-10398 capsule will be administered orally once on Day 1 in Participants With Kidney Dysfunction

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10398 Placebo
Description: SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10398 Placebo
Description: SAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once on Day 1 MAD：HS-10398 capsule placebo (5 predefined dose cohorts ) will be administered orally once or twice from Day 1 to Day 14
Study: NCT04888390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Disease and exercise suggestion
Description: The participants will be provided by educational program about heart failure self-care and home-based exercise approach.
Study: NCT05119894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 1
Description: Cohort 1: Single Dose Intramuscular Injection: Brexpiprazole LAI Dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 2
Description: Cohort 2: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole LAI: Dose 3
Description: Cohort 3: Single Dose Intramuscular Injection:Brexpiprazole LAI Dose 3
Study: NCT04684537

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy (ESWT)
Description: The therapy will be performed with the focused piezoelectric shockwave (F10G4 Richard Wolf GmbH, Germany). The patient will be kept in the hip flexion, adduction and internal rotation position. After sonography-guided localization of the affected muscle and identification of the trigger point by the participant, ultrasound gel is applied to the skin and the applicator couple is placed with an impulse energy flux density of 0.456-0.882 mJ/mm2 for 3500 impulses.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided piriformis steroid injection
Description: all the participants will receive ultrasound-guided piriformis injection with 10 mg triamcinolone and 1 c.c. 1% lidocaine for one time.